State Board of Administration of Florida Retirement System Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

State Board of Administration of Florida Retirement System acquired a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating) during the second quarter, according to its most recent filing with the SEC. The firm acquired 18,504 shares of the biotechnology company’s stock, valued at approximately $258,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC purchased a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth $26,000. Amalgamated Bank purchased a new stake in shares of Aclaris Therapeutics during the 1st quarter worth $143,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth $227,000. Strs Ohio purchased a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth $249,000. Finally, MetLife Investment Management LLC boosted its position in shares of Aclaris Therapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 26,282 shares of the biotechnology company’s stock worth $453,000 after purchasing an additional 9,700 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Aclaris Therapeutics

In related news, insider Joseph Monahan sold 5,000 shares of the business’s stock in a transaction dated Monday, October 17th. The shares were sold at an average price of $15.98, for a total value of $79,900.00. Following the completion of the transaction, the insider now owns 101,386 shares of the company’s stock, valued at approximately $1,620,148.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Joseph Monahan sold 5,000 shares of the company’s stock in a transaction dated Monday, October 17th. The shares were sold at an average price of $15.98, for a total transaction of $79,900.00. Following the completion of the transaction, the insider now owns 101,386 shares of the company’s stock, valued at approximately $1,620,148.28. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Andrew N. Schiff sold 37,839 shares of the company’s stock in a transaction dated Thursday, October 6th. The shares were sold at an average price of $16.54, for a total transaction of $625,857.06. Following the transaction, the director now directly owns 588,916 shares of the company’s stock, valued at approximately $9,740,670.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 99,639 shares of company stock valued at $1,644,933. 6.70% of the stock is owned by insiders.

Aclaris Therapeutics Trading Down 0.7 %

Shares of ACRS stock opened at $18.24 on Tuesday. The firm has a 50-day moving average price of $15.74 and a 200 day moving average price of $15.23. Aclaris Therapeutics, Inc. has a twelve month low of $9.26 and a twelve month high of $18.96. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -14.14 and a beta of 0.55.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. BTIG Research started coverage on shares of Aclaris Therapeutics in a research report on Thursday, October 6th. They set a “buy” rating and a $32.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aclaris Therapeutics in a research report on Monday, August 1st. SVB Leerink reiterated an “outperform” rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th. Finally, StockNews.com started coverage on shares of Aclaris Therapeutics in a research report on Wednesday, October 12th. They issued a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

About Aclaris Therapeutics

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Featured Articles

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.